Mass. Movers

Dyax revenue increases, loss narrows

Shares of Burlington biopharmaceutical company Dyax Corp. rose on fourth-quarter revenue that reached $16.9 million, compared to $16.0 million last year. The loss per share narrowed to 2 cents, beating estimates of a 4-cent loss. Officials reported sales of Kalbitor, Dyax’s lead product, which treats hereditary angioedema, increased to $12.6 million, compared to $11.8 million last year. Hereditary angioedema is a rare problem with the immune system that causes swelling, particularly of the face and airways, and cramping.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of